Pharmaron (03759) Reports Monthly Equity Movements for February 2026

Bulletin Express03-04

Pharmaron Beijing Co., Ltd. (Stock Code: 03759) submitted a monthly update to the Hong Kong Exchanges and Clearing Limited for the period ended 28 February 2026, with the submission date on 04 March 2026.

Pharmaron’s total authorised share capital stood at 1.84 billion shares. Within this structure, H shares remained at 359.98 million, and A shares (listed in Shenzhen) remained at 1.48 billion. There was no change in the volume of either H or A shares during the reporting month.

The outstanding issued H shares totaled 352.71 million at the end of February, while 7.26 million H shares were held in treasury. These treasury H shares remain designated under the “2025 H Share Award and Trust Scheme,” which was initially approved in June 2025.

Pharmaron’s public float requirements for its H shares, as stipulated in the relevant listing rules, remained in compliance during February. No new share issuance or treasury share transfers occurred, and the share incentive plans for A shares, previously approved by the board, did not result in any additional share issuances or transfers. All essential confirmation requirements were met with no noted irregularities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147554570?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 17:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147554570","market":"us","top_or_hot":-1,"title":"Pharmaron (03759) Reports Monthly Equity Movements for February 2026","media":"Bulletin Express","content":"<p>Pharmaron Beijing Co., Ltd. (Stock Code: 03759) submitted a monthly update to the Hong Kong Exchanges and Clearing Limited for the period ended 28 February 2026, with the submission date on 04 March 2026.</p>\n<p>Pharmaron’s total authorised share capital stood at 1.84 billion shares. Within this structure, H shares remained at 359.98 million, and A shares (listed in Shenzhen) remained at 1.48 billion. There was no change in the volume of either H or A shares during the reporting month.</p>\n<p>The outstanding issued H shares totaled 352.71 million at the end of February, while 7.26 million H shares were held in treasury. These treasury H shares remain designated under the “2025 H Share Award and Trust Scheme,” which was initially approved in June 2025.</p>\n<p>Pharmaron’s public float requirements for its H shares, as stipulated in the relevant listing rules, remained in compliance during February. No new share issuance or treasury share transfers occurred, and the share incentive plans for A shares, previously approved by the board, did not result in any additional share issuances or transfers. All essential confirmation requirements were met with no noted irregularities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharmaron (03759) Reports Monthly Equity Movements for February 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaron (03759) Reports Monthly Equity Movements for February 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-04 17:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pharmaron Beijing Co., Ltd. (Stock Code: 03759) submitted a monthly update to the Hong Kong Exchanges and Clearing Limited for the period ended 28 February 2026, with the submission date on 04 March 2026.</p>\n<p>Pharmaron’s total authorised share capital stood at 1.84 billion shares. Within this structure, H shares remained at 359.98 million, and A shares (listed in Shenzhen) remained at 1.48 billion. There was no change in the volume of either H or A shares during the reporting month.</p>\n<p>The outstanding issued H shares totaled 352.71 million at the end of February, while 7.26 million H shares were held in treasury. These treasury H shares remain designated under the “2025 H Share Award and Trust Scheme,” which was initially approved in June 2025.</p>\n<p>Pharmaron’s public float requirements for its H shares, as stipulated in the relevant listing rules, remained in compliance during February. No new share issuance or treasury share transfers occurred, and the share incentive plans for A shares, previously approved by the board, did not result in any additional share issuances or transfers. All essential confirmation requirements were met with no noted irregularities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1147554570","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147554570","pubTimestamp":1772615878,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Pharmaron Beijing Co., Ltd. (Stock Code: 03759) submitted a monthly update to the Hong Kong Exchanges and Clearing Limited for the period ended 28 February 2026, with the submission date on 04 March...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"康龙化成(03759)2026年2月权益变动月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"Pharmaron Beijing Co., Ltd. (Stock Code: 03759) submitted a monthly update to the Hong Kong Exchanges and Clearing Limited for the period ended 28 February 2026, with the submission date on 04 March 2026.\nPharmaron’s total authorised share capital stood at 1.84 billion shares. Within this structure, H shares remained at 359.98 million, and A shares (listed in Shenzhen) remained at 1.48 billion. There was no change in the volume of either H or A shares during the reporting month.\nThe outstanding issued H shares totaled 352.71 million at the end of February, while 7.26 million H shares were held in treasury. These treasury H shares remain designated under the “2025 H Share Award and Trust Scheme,” which was initially approved in June 2025.\nPharmaron’s public float requirements for its H shares, as stipulated in the relevant listing rules, remained in compliance during February. No new share issuance or treasury share transfers occurred, and the share incentive plans for A shares, previously approved by the board, did not result in any additional share issuances or transfers. All essential confirmation requirements were met with no noted irregularities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147554570","isCrawlerRequest":true}